| Title |
Mirogabalin and emerging therapies for diabetic neuropathy
|
|---|---|
| Published in |
Journal of Pain Research, August 2018
|
| DOI | 10.2147/jpr.s145999 |
| Pubmed ID | |
| Authors |
Saad Javed, Uazman Alam, Rayaz A Malik |
| Abstract |
There are currently no approved disease-modifying therapies for diabetic neuropathy, and there are only 3 US Food and Drug Administration-approved therapies (pregabalin, duloxetine, and tapentadol) for painful diabetic neuropathy. They each have moderate efficacy with adverse effects limiting optimal dose titration. There is a considerable need for new therapies for the management of painful diabetic neuropathy. We reviewed the potential role of mirogabalin, which like gabapentin and pregabalin modulates the alpha-2/delta-1 subunit of the voltage-gated calcium channel, allowing the influx of calcium and release of neurotransmitters at the synaptic cleft in the central nervous system and spinal cord. It has shown efficacy and good tolerability in a Phase II study in diabetic painful neuropathy and based on the results of two Phase III clinical trials in diabetic painful neuropathy and post-herpetic neuralgia, Daiichi Sankyo submitted a marketing application for neuropathic pain in Japan in February 2018. We have also reviewed potential new therapies, currently in Phase II clinical trials that may modify disease and/or relieve neuropathic pain through novel modes of action. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 67% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 67% |
| Scientists | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 61 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 8 | 13% |
| Researcher | 6 | 10% |
| Student > Ph. D. Student | 5 | 8% |
| Student > Doctoral Student | 5 | 8% |
| Student > Master | 4 | 7% |
| Other | 12 | 20% |
| Unknown | 21 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 24 | 39% |
| Biochemistry, Genetics and Molecular Biology | 3 | 5% |
| Neuroscience | 3 | 5% |
| Agricultural and Biological Sciences | 1 | 2% |
| Computer Science | 1 | 2% |
| Other | 5 | 8% |
| Unknown | 24 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 August 2018.
All research outputs
#15,048,620
of 25,584,565 outputs
Outputs from Journal of Pain Research
#1,013
of 1,969 outputs
Outputs of similar age
#176,018
of 342,399 outputs
Outputs of similar age from Journal of Pain Research
#33
of 60 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,969 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.3. This one is in the 47th percentile – i.e., 47% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 342,399 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 60 others from the same source and published within six weeks on either side of this one. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.